2-(1-氯乙基)-3,1-苯并恶嗪-4-酮 | 89441-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 2-(1-氯乙基)-3,1-苯并恶嗪-4-酮
• 英文名称: 2-(1-chloroethyl)-3,1-benzoxazin-4(3H)-one
• 英文别名: 2-(1-chloroethyl)-4H-3,1-benzoxazine-4-one；2-(1-Chloroethyl)-4H-3,1-benzoxazin-4-one；2-(1-chloroethyl)-3,1-benzoxazin-4-one
• CAS: 89441-13-4
• 化学式: C₁₀H₈ClNO₂
• 分子量: 209.632
• InChiKey: DTGJFDPCOHJEBM-UHFFFAOYSA-N

物化性质

• 沸点：
  323.0±44.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1-氯乙基)-3,1-苯并恶嗪-4-酮 在 乙酸铵 、 zinc(II) chloride 作用下， 反应 2.0h， 以65%的产率得到2-(1-chloroethyl)-quinazolin-4(3H)-one
  参考文献：
  名称：

  Sayed, M A; El-Kafrawy, A F; Soliman, A Y, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1991, vol. 30, # 10, p. 980 - 983

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(α-chloropropionyl)anthranilic acid 在 乙酸酐 作用下， 反应 2.0h， 以72%的产率得到2-(1-氯乙基)-3,1-苯并恶嗪-4-酮
  参考文献：
  名称：

  Sayed, M A; El-Kafrawy, A F; Soliman, A Y, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1991, vol. 30, # 10, p. 980 - 983

  摘要：

  DOI：

文献信息

• 4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities
  作者：Francois Clemence、Odile Le Martret、Francoise Delevallee、Josette Benzoni、Alain Jouanen、Simone Jouquey、Michel Mouren、Roger Deraedt

  DOI：10.1021/jm00402a034

  日期：1988.7

  by the oral route as antiinflammatory agents in carrageenin-induced foot edema and adjuvant-induced arthritis and as analgesic agents in the acetic acid induced writhing test. Among the most active molecules, some have shown both analgesic and acute antiinflammatory activities. Others, such as compounds 24, 37, and 52, were only powerful peripherally acting analgesics. Compound 52, being active at 1

  已经合成了一系列的4-羟基-3-喹啉甲酰胺，并通过口服途径评价了角叉菜胶引起的足部水肿和佐剂引起的关节炎中的抗炎药，以及乙酸引起的扭体试验中的镇痛药。在最活跃的分子中，有些已经显示出止痛和急性抗炎活性。其他化合物，例如化合物24、37和52，仅是有效的外周镇痛药。活性为1 mg / kg（ED50）的化合物52是该系列中最有效的化合物。一些在2位上被醇，酯或胺官能团取代的类似物显示出与吡罗昔康相同的有效抗关节炎活性，并且在炎症和伤害感受的急性试验中也具有活性。他们抑制了微摩尔浓度的环氧合酶和5-脂氧合酶的活性。化合物102（RU 43526）显示出有效的抗关节炎活性（佐剂诱发的关节炎，ED50 = 0.7 mg / kg，口服）和胃肠道耐受性（ED100大于250 mg / kg，口服），因此，目前正在接受广泛的药理评估。
• Certain 1,3-dihydro-1-[heterocyclic)imino]-furo-[3,4-b]quinoline 9-ol
  申请人：Roussel Uclaf

  公开号：US04736033A1

  公开（公告）日：1988-04-05

  A 4-hydroxy-3-quinoline-carboxamides of the formula ##STR1## wherein X is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CH.sub.3, --OCF.sub.3 or --SCF.sub.3, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R.sub.2 is selected from the group consisting of a heterocycle connected to the nitrogen by a carbon atom selected from thiazolyl, 4,5-dihydro-thiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidinyl or tetrazolyl, all optionally substituted with alkyl of 1 to 4 carbon atoms or phenyl optionally substituted with at least one member of the group consisting of --OH, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CH.sub.3, --NO.sub.2 or halogen, R.sub.3 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms or aryl, R.sub.4 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms or aryl, and their non-toxic, pharmaceutically acceptable acid addition salts and salts with non-toxic, pharmaceutically acceptable bases having very good analgesis activity and a non-negligible anti-inflammatory activity and novel intermediates.

  式##STR1##中的4-羟基-3-喹啉羧酰胺，其中X位于5、6、7或8位，并选自由氢、卤素、1至5个碳原子的烷基、1至4个碳原子的烷氧基、--CH.sub.3、--OCF.sub.3或--SCF.sub.3的群，R.sub.1选自由氢和1至4个碳原子的烷基的群，R.sub.2选自由氮原子连接的杂环，所述杂环由噻唑基、4,5-二氢噻唑基、吡啶基、噁唑基、异噁唑基、咪唑基、嘧啶基或四唑基中的碳原子选自，所有这些基可选择地用1至4个碳原子的烷基或苯基取代，所述苯基可选择地用--OH、1至4个碳原子的烷基、1至4个碳原子的烷氧基、--CH.sub.3、--NO.sub.2或卤素中的至少一种成员取代，R.sub.3选自由氢、1至4个碳原子的烷基或芳基的群，R.sub.4选自由氢、1至4个碳原子的烷基或芳基的群，以及它们的无毒、药学上可接受的酸盐和与非毒性、药学上可接受的碱形成的盐，具有非常好的镇痛活性和非可忽略的抗炎活性和新颖的中间体。
• 4-Hydroxy-3-quinoline-carboxylic acid derivatives
  申请人：Roussel Uclaf

  公开号：US04486438A1

  公开（公告）日：1984-12-04

  Novel 4-hydroxy-3-quinoline-carboxamides of the formula ##STR1## wherein X is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CF.sub.3, --OCF.sub.3 and --SCF.sub.3, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R.sub.2 is selected from the group consisting of thiazolyl, 4,5-dihydro-thiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidinyl and tetrazolyl, all optionally substituted with alkyl of 1 to 4 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of --OH, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CF.sub.3, --NO.sub.2 and halogen R.sub.3 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and aryl, R.sub.4 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and aryl, R.sub.5 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and ##STR2## R.sub.5 ' is selected from the group consisting of alkyl of 1 to 4 carbon atoms and aryl and their non-toxic, pharmaceutically acceptable acid addition salts and salts with non-toxic, pharmaceutically acceptable bases having very good analgesic activity and a non-negligible anti-inflammatory activity and novel intermediates.

  新型4-羟基-3-喹啉羧酰胺的化学式为##STR1##其中X位于5,6,7或8位，并选自由氢、卤素、1至5个碳原子的烷基、1至4个碳原子的烷氧基、--CF.sub.3、--OCF.sub.3和--SCF.sub.3组成的群，R.sub.1选自由氢和1至4个碳原子的烷基组成的群，R.sub.2选自噻唑基、4,5-二氢噻唑基、吡啶基、噁唑基、异噁唑基、咪唑基、嘧啶基和四唑基组成的群，所有这些基可选择地用1至4个碳原子的烷基和苯基替代，所述苯基可选择地用--OH、1至4个碳原子的烷基、1至4个碳原子的烷氧基、--CF.sub.3、--NO.sub.2和卤素中的至少一种成员替代，R.sub.3选自由氢、1至4个碳原子的烷基和芳基组成的群，R.sub.4选自由氢、1至4个碳原子的烷基和芳基组成的群，R.sub.5选自由氢、1至4个碳原子的烷基和##STR2##R.sub.5'选自由1至4个碳原子的烷基和芳基组成的群，以及它们的无毒、药学上可接受的酸盐和与无毒、药学上可接受的碱盐具有非常好的镇痛活性和不可忽视的抗炎活性的盐和新型中间体。
• Preparation of amides of 4-hydroxy-3-quinoline-carboxylic acid
  申请人：Roussel Uclaf

  公开号：US04596875A1

  公开（公告）日：1986-06-24

  Novel 4-hydroxy-3-quinoline-carboxamides of the formula ##STR1## wherein X is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CF.sub.3, --OCF.sub.3 and --SCF.sub.3, R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 4 carbon atoms, R.sub.2 is selected from the group consisting of thiazolyl, 4,5-dihydro-thiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidinyl and tetrazolyl, all optionally substituted with alkyl of 1 to 4 carbon atoms and phenyl optionally substituted with at least one member of the group consisting of --OH, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, --CF.sub.3, --NO.sub.2 and halogen, R.sub.3 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and aryl, R.sub.4 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and aryl, R.sub.5 is selected from the group consisting of hydrogen, alkyl of 1 to 4 carbon atoms and ##STR2## R.sub.5 ' is selected from the group consisting of alkyl of 1 to 4 carbon atoms and aryl and their non-toxic, pharmaceutically acceptable acid addition salts and salts with non-toxic, pharmaceutically acceptable bases having very good analgesic activity and a non-negligible anti-inflammatory activity and novel intermediates.

  化合物的名称为4-羟基-3-喹啉甲酰胺，化学式如下：##STR1## 其中X位于5、6、7或8位，选自氢、卤素、1至5个碳原子的烷基、1至4个碳原子的烷氧基、--CF.sub.3、--OCF.sub.3和--SCF.sub.3的群组，R.sub.1选自氢和1至4个碳原子的烷基，R.sub.2选自噻唑基、4,5-二氢噻唑基、吡啶基、噁唑基、异噁唑基、咪唑基、嘧啶基和四唑基，均可选用1至4个碳原子的烷基和苯基，后者可选择至少一种取代基，所述取代基选自--OH、1至4个碳原子的烷基、1至4个碳原子的烷氧基、--CF.sub.3、--NO.sub.2和卤素的群组，R.sub.3选自氢、1至4个碳原子的烷基和芳基，R.sub.4选自氢、1至4个碳原子的烷基和芳基，R.sub.5选自氢、1至4个碳原子的烷基和##STR2##，R.sub.5'选自1至4个碳原子的烷基和芳基。该化合物及其中间体具有很好的镇痛活性和非常重要的抗炎活性，以及其非毒性、药学上可接受的酸盐和非毒性、药学上可接受的碱盐。
• CLEMENCE, FRANCOIS;LE, MARTRET ODILE;DELEVALLEE, FRANCOISE;BENZONI, JOSET+, J. MED. CHEM., 31,(1988) N 7, C. 1453-1462
  作者：CLEMENCE, FRANCOIS、LE, MARTRET ODILE、DELEVALLEE, FRANCOISE、BENZONI, JOSET+

  DOI：——

  日期：——